预披露公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-040 广州迈普再生医学科技股份有限公司 关于公司首发前股东减持股份的预披露公告 公司首发前股东国寿成达（上海）健康产业股权投资中心（有限合伙）保 证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 1、截至本公告披露日，国寿成达（上海）健康产业股权投资中心（有限合 伙）（以下简称"国寿成达"或"本企业"）持有广州迈普再生医学科技股份有 限公司（以下简称"公司"）3,267,436 股，占公司总股本的 4.9120%（占剔除 公司回购专用账户股份数量后总股本的 4.9382%）。 2、国寿成达系 2016 年 12 月在中国证券投资基金业协会完成备案的私募基 金，基金编号为 SN4372。 3、国寿成达因自身经营需要，计划通过集中竞价交易及大宗交易方式合计 减持公司股份不超过 1,995,582 股，占公司总股本的 3.0000%（占剔除公司回购 专用账户股份数量后总股本的 3.0160%）。其中，通过集中竞价方式减持不超过 ...

迈普医学(301033.SZ)公告称，公司首发前股东国寿成达计划通过集中竞价交易及大宗交易方式合计减 持公司股份不超过1,995,582股，占公司总股本的3.0000%（占剔除公司 回购专用账户股份数量后总股本 的3.0160%）。 ...

Investment Rating - The investment rating for the company is "Buy" [2] Core Views - The company, Maipu Medical, is a leading player in the domestic neurosurgery field, focusing on high-performance implantable medical devices. The company is expected to enter a growth phase by continuously enriching its product portfolio and improving marketing channels. Key products include artificial dura mater (spinal) patches, which are expected to see accelerated market penetration due to centralized procurement, and new products like absorbable hemostatic gauze and dura mater glue, which are anticipated to provide sustained growth momentum [6][14][17]. Summary by Sections Company Overview - Maipu Medical, established in 2008 and listed on the Shenzhen Stock Exchange in 2021, specializes in high-performance implantable medical devices for neurosurgery. The company has developed a range of products including dura mater repair products and craniofacial repair systems, enhancing its capability to provide comprehensive solutions in neurosurgical repair [17][18]. Product Performance - The artificial dura mater (spinal) patch is a cornerstone product benefiting from centralized procurement, with projected revenue of 156 million yuan in 2024, reflecting a year-on-year growth of 11.46%. The product's unique bionic structure offers advantages in biocompatibility and degradability [15][32]. - Craniofacial repair products are expected to generate 80 million yuan in revenue in 2024, with a year-on-year growth of 31.05%. The superior properties of PEEK materials are anticipated to drive market penetration, replacing traditional titanium materials [16][44]. - The absorbable hemostatic gauze is projected to achieve revenue of 36 million yuan in 2024, with a year-on-year growth of 49.89%. This product is expected to break the import monopoly and rapidly gain market share [16][49]. Financial Projections - Revenue forecasts for the company from 2025 to 2027 are 371 million yuan, 491 million yuan, and 647 million yuan, with year-on-year growth rates of 33.1%, 32.5%, and 31.8% respectively. Net profit attributable to the parent company is expected to be 113 million yuan, 149 million yuan, and 199 million yuan for the same period, with growth rates of 43.6%, 31.8%, and 33.4% respectively [6][7][28]. Market Position - The company is the only domestic enterprise with a comprehensive product line in the neurosurgery field, including artificial dura mater patches, craniofacial repair systems, and absorbable hemostatic products. This diverse product structure is expected to support stable revenue growth and long-term sustainable development [18][30].

Core Viewpoint - The article discusses the recent adjustments in stock holdings by various fund managers and institutions, highlighting contrasting strategies and significant movements in specific sectors such as medical devices, renewable energy, and high-end manufacturing [1][2][5][9]. Group 1: Medical Sector Adjustments - Fund managers Ge Lan and Wu Xingwu have shown "reverse operations" regarding Mai Pu Medical, with Ge Lan's fund entering the top ten shareholders while Wu Xingwu exited [1][2]. - Mai Pu Medical's stock price has increased by 37.52% year-to-date, with a cumulative rise of 18.16% in the second quarter [2]. - After reducing holdings in Jianyou shares, Ge Lan's fund has also exited the top ten shareholders of Jianyou, which has seen a cumulative decline of 19.1% in the second quarter [2]. Group 2: Adjustments in Renewable Energy Sector - Zheng Chengran has made significant adjustments in the photovoltaic sector, notably increasing holdings in Guodewei by 95.19% while exiting Daqian Energy [5][6]. - Guodewei's stock has experienced a cumulative decline of 9.37% in the second quarter, while Daqian Energy reported a 69.57% year-on-year revenue drop in the first quarter [5]. - Contrasting strategies are evident as Zhao Yi has continuously increased his holdings in De Ye shares, while Zheng Chengran has reduced his [6]. Group 3: Military and Semiconductor Sector Movements - Fund managers from Yongying Fund have shown differing strategies in military stocks, with a significant increase in holdings of Beifang Changlong by 56.9% from one manager, while another has exited the top ten shareholders [7]. - In the semiconductor sector, notable reductions in holdings of Ju Guang Technology have been observed, with a decrease of 20.45% [7][8]. Group 4: Institutional Adjustments - Domestic brokerages and foreign institutions have also made notable adjustments, primarily focusing on high-end manufacturing and chemical new materials [9][11]. - Notably, Morgan Stanley and JPMorgan have exited several top shareholder positions, including those in North Changlong and Aipu shares, while also increasing their stakes in Xusheng Group [9][10]. - The article highlights a divergence in strategies, with Abu Dhabi Investment Authority increasing its stake in Baofeng Energy while CITIC Securities has reduced its holdings [11].

Core Viewpoint - The acquisition of Easy Medical Technology by Maipu Medical has raised concerns due to the target company's significant losses and the potential for conflicts of interest, as both companies are controlled by the same individual [2][4][6]. Company Overview - Maipu Medical is a high-tech enterprise focused on developing high-performance implantable medical devices, particularly in the field of neurosurgery [3]. - Easy Medical Technology specializes in providing minimally invasive solutions for cerebrovascular diseases, with products including neuro-interventional catheters and thrombectomy devices [3]. Financial Performance - Easy Medical is projected to incur cumulative net losses exceeding 55 million yuan in 2023 and 2024, while Maipu Medical reported a net profit of 78.85 million yuan in the previous year [2][3]. - In 2023, Easy Medical's revenue was approximately 11.94 million yuan, with a net loss of about 29.51 million yuan, and in 2024, revenue is expected to reach 24.41 million yuan with a net loss of 26.16 million yuan [3]. Acquisition Details - The acquisition aims to expand Maipu Medical's product offerings in the neurosurgery field and integrate channel resources [3][4]. - The transaction involves issuing shares and cash to acquire 100% of Easy Medical, with additional funds raised from the actual controller for transaction-related costs [2]. Concerns and Risks - The transaction has been criticized for its lack of transparency regarding the valuation of Easy Medical, as the board approved the acquisition without a completed audit or assessment [4][6]. - There are concerns about potential conflicts of interest due to the intertwined ownership structures of the companies involved, leading to accusations of a "left hand to right hand" transaction [4][6]. Market Reaction - Following the announcement of the acquisition, Maipu Medical's stock price fell nearly 12% on the first trading day after resuming trading, reflecting investor skepticism about the fairness of the transaction [2][6]. Strategic Rationale - The acquisition is seen as a strategic move to tap into the growing neurovascular intervention market, which is projected to reach 43.2 billion yuan by 2028, with a compound annual growth rate of 36.5% [9][10]. - Maipu Medical aims to leverage its expertise in synthetic materials to develop innovative medical devices in the interventional field, potentially creating a comprehensive solution platform for neurosurgery [7][10].

股东大会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-038 广州迈普再生医学科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生。 2、本次股东大会不涉及变更前次股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 年 6 月 13 日下午 14:30 以现场表决和网络投票相结合的方式召 开公司 2025 年第一次临时股东大会。 1、会议召开时间：2025 年 6 月 13 日（星期五）下午 14:30 2、会议召开地点：广州市黄埔区崖鹰石路 3 号迈普医学大厦会 议室 3、会议召开方式：采取现场表决与网络投票相结合的方式。现 场会议召开时间：2025 年 6 月 13 日（星期五）。网络投票时间：通 过深圳证券交易所交易系统进行网络投票的时间为：2025 年 6 月 13 日（星期五）上午 9:15-9:25，9:30-11:30 和下午 13 ...

广州迈普再生医学科技股份有限公司 关于董事辞任暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于非独立董事辞任的情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）收到 公司非独立董事郑海莹女士的书面辞任报告。因个人原因，郑海莹女 士申请辞去公司第三届董事会非独立董事职务，辞任后亦不担任公司 相关职务。郑海莹女士原定的任职期间为至第三届董事会任期届满之 日，其辞任不会导致公司董事会人数低于法定最低人数，其辞任报告 自送达公司之日起生效，辞职后不在公司及子公司担任任何职务。郑 海莹女士将按照公司相关规定做好离任交接工作。 董事辞任暨选举职工董事的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-039 董事辞任暨选举职工董事的公告 大会民主选举，选举林洁芬女士（简历详见附件）担任公司第三届董 事会职工董事，任期至第三届董事会任期届满之日。 林洁芬女士符合《公司法》《公司章程》规定的有关职工董事任 职资格和条件。林洁芬女士当选公司职工董事后，公司第三届董事会 中兼任公司高级管理人员职务的董事以及由职工代表担 ...

北京市中伦（广州）律师事务所 关于广州迈普再生医学科技股份有限公司 2025 年第一次临时股东大会 关于广州迈普再生医学科技股份有限公司 2025 年第一次临时股东大会 的法律意见书 致：广州迈普再生医学科技股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）接受广州迈普再生医 学科技股份有限公司（以下简称"公司"）委托，指派孙巧芬律师和曾思律师（以 下简称"本所律师"）对公司 2025 年第一次临时股东大会（以下简称"本次股 东大会"）的合法性进行见证并出具法律意见。 的法律意见书 二〇二五年六月 北京市中伦（广州）律师事务所 本所及本所律师依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则（试行）》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格 履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保 证本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 本法律意见书根据《中华人民共和国公司法》（以下简称"《 ...

Group 1 - Multiple pharmaceutical and technology stocks have seen increased holdings from active equity funds due to recent corporate actions such as restructuring and buybacks [1][6] - MaiPu Medical announced a plan to acquire 100% of YiJie Medical, focusing on expanding its business in the neurointerventional medical device sector [2] - The healthcare sector is experiencing a rebound, with active interest from public fund managers in companies like MaiPu Medical, which has seen significant attention from various fund managers during investor relations activities [2][3] Group 2 - The performance of the healthcare sector has been strong, with the China Europe Medical Health fund increasing by 11.6% year-to-date, while the China Europe Medical Innovation fund has surged by 37.34% [3] - The increase in fund performance is attributed to strategic investments in Hong Kong-listed pharmaceutical stocks and successful positioning in high-performing stocks like BaiLi TianHeng [3] - The medical device sector is expected to continue its recovery, supported by a resurgence in domestic bidding and inventory digestion, which will positively impact company performance [4] Group 3 - Recent buyback announcements from companies like BeiFang LongChuang and GuDeWei indicate a trend of active equity funds maintaining or increasing their holdings in high-tech stocks [6] - Specific funds, such as YongYing RuiJian and YongYing KeJi, have been noted for increasing their stakes in companies like BeiFang LongChuang [6] - Some companies, like Shandong GaoSu, have experienced reductions in fund holdings, indicating a mixed sentiment among fund managers [7]

Group 1: Fundraising and Investment Trends - Several new pharmaceutical-themed funds have shortened their fundraising periods due to rapid stock price increases in innovative drugs, with some funds ending their fundraising early, such as the Dongfang Alpha Health Industry Fund, which closed on June 10 instead of June 13 [1] - The Ping An Hong Kong Stock Connect Medical Innovation Selected Fund also announced an early closure of its fundraising, originally set to end on June 25 [1] Group 2: Bond Fund Restrictions - Over ten public fund institutions, including China Merchants Fund and Dongfang Fund, announced restrictions on large subscriptions for certain bond funds, with varying limits on subscription amounts [2] - For instance, the Dongfang Zhenyu Bond Fund has a subscription limit of 10,000 yuan, while several funds under ICBC Credit Suisse have a limit of 10 million yuan for institutional investors starting June 11 [2] Group 3: Fund Performance Recovery - More than 60% of actively managed equity funds have recovered from previous performance declines, driven by sectors such as innovative drugs, new consumption, gold, and AI, with some funds seeing net value rebounds of over 30% in the past two months [4] - Funds like Changcheng Pharmaceutical Industry Selected A and Zhonghang Preferred Navigation A have shown significant performance improvements, with year-to-date returns exceeding 70% [4] Group 4: New Fund Share Classes - Public funds have been increasingly announcing the addition of new "niche" share classes, such as E shares for Ping An CSI A50 ETF and D shares for Jiahe Panheng Bond Fund, indicating a trend towards diversifying fund offerings [5] - The increase in "niche" share classes, particularly for fixed-income and index products, contrasts with the more common addition of B and C shares in the past [5] Group 5: Market Activity and ETF Performance - On June 11, the market experienced a rebound, with the Shanghai Composite Index rising by 0.52% and the Shenzhen Component Index by 0.83%, while the total trading volume was 1.26 trillion yuan, down by 159.9 billion yuan from the previous trading day [8] - Sectors such as rare metals and gaming saw significant gains, while biopharmaceuticals and communication services faced declines [8][9]